NYSE:ANVS Annovis Bio Q3 2026 Earnings Results & Report $0.95 +0.10 (+11.66%) As of 12:54 PM Eastern This is a fair market value price provided by Massive. Learn more. Annovis Bio beat analyst earnings expectations in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$0.22 versus the -$0.2967 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 13, 2026TimeBefore Market OpensConference Call DateNovember 17, 2026Conference Call12:30 PM ET Annovis Bio EPS ResultsActual EPS-$0.22Consensus EPS -$0.2967Beat/MissBeat by +$0.0767One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersAnnovis Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Annovis Bio Q3 2026 Earnings FAQ Did Annovis Bio beat earnings estimates for Q3 2026? Annovis Bio (NYSE:ANVS) reported earnings of -$0.22 per share for Q3 2026, beating the consensus estimate of -$0.2967. The report was announced on Friday, November 13, 2026. Annovis Bio Earnings HeadlinesAnnovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results4 hours ago | globenewswire.comAnnovis Bio Granted U.S. Patent Covering New Crystalline Form of BuntanetapNovember 12 at 9:45 AM | markets.businessinsider.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 13 at 1:00 AM | Base Camp Trading (Ad)Annovis Bio (ANVS) Projected to Post Earnings on WednesdayNovember 10 at 2:10 AM | americanbankingnews.comAnnovis Closes $21 Million Offering, Funds Operations Through Phase 3 Alzheimer's Readout; Stock UpNovember 9, 2026 | rttnews.comAnnovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board ChairmanNovember 9, 2026 | markets.businessinsider.comSee More Annovis Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Annovis Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annovis Bio and other key companies, straight to your email. Email Address About Annovis BioAnnovis Bio (NYSE:ANVS) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. The company’s research centers on therapies designed to address mechanisms associated with neurodegeneration rather than treating only individual symptoms. Annovis Bio’s lead product candidate is buntanetap, formerly known as ANVS401. Buntanetap is an orally administered small molecule being investigated for its potential to reduce the production of multiple neurotoxic proteins linked to neurodegenerative disorders. The candidate has been evaluated in clinical studies involving patients with Alzheimer’s and Parkinson’s disease. Founded in 2008, Annovis Bio is headquartered in Berwyn, Pennsylvania. The company operates as a development-stage biotechnology business and does not currently have an approved commercial product. Annovis Bio is led by Maria L. Maccecchini, Ph.D., who serves as chief executive officer and has been involved in the company’s development of therapies for neurodegenerative diseases.View Annovis Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
